BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 11441411)

  • 41. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801.
    Maemondo M; Inoue A; Sugawara S; Harada T; Minegishi Y; Usui K; Miwa K; Morikawa N; Kambe M; Ube K; Watanabe K; Ishimoto O; Sakakibara T; Gemma A; Nukiwa T
    Oncologist; 2014 Apr; 19(4):352-3. PubMed ID: 24682465
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors.
    Dumez H; Louwerens M; Pawinsky A; Planting AS; de Jonge MJ; Van Oosterom AT; Highley M; Guetens G; Mantel M; de Boeck G; de Bruijn E; Verweij J
    Anticancer Drugs; 2002 Jul; 13(6):583-93. PubMed ID: 12172503
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase I trial of docetaxel and gemcitabine in patients with advanced cancer.
    Rischin D; Boyer M; Smith J; Millward M; Michael M; Bishop J; Zalcberg J; Davison J; Emmett E; McClure B
    Ann Oncol; 2000 Apr; 11(4):421-6. PubMed ID: 10847460
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
    Casal J; Amenedo M; Mel JR; Antón LM; Rodríguez-López R; López-López R; González-Ageitos A; Castellanos J; Constenla M; Tisaire JL
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):725-32. PubMed ID: 17273825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor.
    Hejna M; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger WC; Marosi L; Schneeweiss B; Greul R; Scheithauer W
    Cancer; 2000 Aug; 89(3):516-22. PubMed ID: 10931450
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.
    Ardavanis A; Tryfonopoulos D; Alexopoulos A; Kandylis C; Lainakis G; Rigatos G
    Br J Cancer; 2005 Feb; 92(4):645-50. PubMed ID: 15685232
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Challenging the platinum combinations in the chemotherapy of NSCLC.
    Douillard JY; Eckardt J; Scagliotti GV
    Lung Cancer; 2002 Dec; 38 Suppl 4():21-8. PubMed ID: 12480191
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
    Herbst RS; Khuri FR; Lu C; Liu DD; Fossella FV; Glisson BS; Pisters KM; Shin DM; Papadimitrakopoulou VA; Kurie JM; Blumenschein G; Kies MS; Zinner R; Jung MS; Lu R; Lee JJ; Munden RF; Hong WK; Lee JS
    Cancer; 2002 Jul; 95(2):340-53. PubMed ID: 12124835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Docetaxel].
    Takigawa N
    Nihon Rinsho; 2002 May; 60 Suppl 5():349-52. PubMed ID: 12101686
    [No Abstract]   [Full Text] [Related]  

  • 51. Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).
    Hosoe S; Komuta K; Shibata K; Harada H; Iwamoto Y; Ohsaki Y; Morioka T; Origasa H; Fukushima M; Furuse K; Kawahara M
    Br J Cancer; 2003 Feb; 88(3):342-7. PubMed ID: 12569374
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma.
    Lilenbaum RC; Schwartz MA; Seigel L; Belette F; Blaustein A; Wittlin FN; Davila E
    Cancer; 2001 Oct; 92(8):2158-63. PubMed ID: 11596033
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.
    Hainsworth JD; Burris HA; Erland JB; Morrissey LH; Meluch AA; Kalman LA; Hon JK; Scullin DC; Smith SW; Greco FA
    Cancer; 1999 Mar; 85(6):1269-76. PubMed ID: 10189131
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bi-weekly administration of gemcitabine plus vinorelbine in elderly patients with advanced non-small-cell lung cancer: multicenter phase II trial.
    Araya T; Kasahara K; Kimura H; Shibata K; Kita T; Shirasaki H; Hara J; Yoshimi Y; Sone T; Oribe Y; Nobata K; Nishi K; Fujimura M; Nakao S;
    Lung Cancer; 2007 Jun; 56(3):371-6. PubMed ID: 17300851
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.
    Miller VA; Kris MG
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):3-10. PubMed ID: 10810932
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer.
    Niho S; Ohe Y; Kakinuma R; Kubota K; Matsumoto T; Ohmatsu H; Goto K; Nishiwaki Y
    Lung Cancer; 2002 Feb; 35(2):209-14. PubMed ID: 11804695
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial.
    Georgoulias V; Samonis G; Papadakis E; Alexopoulos A; Tsiafaki X; Rapti A; Veslemes M; Grigoratou T; Palamidas P; Kouroussis C; Mavroudis D; Kakolyris S; Giannakakis T; Vlachonikolis J;
    Lung Cancer; 2001 Dec; 34 Suppl 4():S47-51. PubMed ID: 11742702
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non--small cell lung cancer.
    Lynch TJ
    Semin Oncol; 2001 Jun; 28(3 Suppl 9):5-9. PubMed ID: 11444253
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy.
    Mori K; Kamiyama Y; Kondo T; Kano Y; Kodama T
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):189-95. PubMed ID: 17096163
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Single agent docetaxel plus granulocyte-colony stimulating factor (G-CSF) in previously treated patients with advanced non small cell lung cancer. A phase II study and review of the literature.
    Gridelli C; Frontini L; Barletta E; Rossi A; Barzelloni ML; Scognamiglio F; Guida C; Gatani T; Fiore F; De Bellis M; Marfella A; Manzione L
    Anticancer Res; 2000; 20(2B):1077-84. PubMed ID: 10810400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.